IL6 and plasma cell myeloma: Although the early findings describing the IL‐6 dependence of plasma cell myeloma cells had generated a strong interest in the IL‐6 signaling complex as a therapeutic target in this disease, the initial clinical trials were disappointing; a phase II trial in high‐risk smoldering myeloma patients is ongoing (Matthes et al, 2016).